Ownership and insider activity for Black Diamond Therapeutics, Inc. (BDTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
Price
| Price | $1.94 |
| Market Cap | $111M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-26 | Behbahani Ali | A-Award | 40,000 | $68K |
| 2026-06-26 | Kulkarni Samarth | A-Award | 40,000 | $68K |
| 2026-06-26 | Menzel Garry E | A-Award | 40,000 | $68K |
| 2026-06-26 | Raman Prakash | A-Award | 40,000 | $68K |
| 2026-06-26 | Dhingra Kapil | A-Award | 40,000 | $68K |
| 2026-06-26 | Campbell Shannon | A-Award | 40,000 | $68K |
| 2026-06-19 | Behbahani Ali | A-Award | 8,961 | $15K |
| 2026-06-19 | Raman Prakash | A-Award | 7,907 | $13K |
| 2026-03-20 | Behbahani Ali | A-Award | 6,919 | $15K |
| 2026-03-20 | Raman Prakash | A-Award | 6,105 | $13K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $51.7M | $154.7M | $34.6M | $65.8M | $34.3M | $56.2M | $36.4M | $21.0M |
| Short-term Investments | 0 | 0 | 0 | $280.5M | $144.0M | $88.5M | $75.2M | $62.1M | $107.7M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $7.9M | $51.7M | $155.7M | $319.6M | $215.7M | $127.7M | $134.0M | $101.2M | $132.4M |
| Property, Plant & Equipment | $102000 | $134000 | $164000 | $8.8M | $30.7M | $27.4M | $23.7M | $20.4M | $9.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $8.0M | $51.8M | $158.3M | $329.7M | $247.7M | $156.3M | $158.6M | $122.6M | $143.0M |
| Accounts Payable | $152000 | $416000 | $2.0M | $2.5M | $4.1M | $1.9M | $2.3M | $4.0M | $579000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.2M | $2.6M | $4.9M | $14.2M | $23.6M | $15.3M | $19.6M | $20.6M | $15.7M |
| Long-term Debt | 0 | $60.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $14.7M | $67.4M | $205.5M | $21.9M | $51.8M | $40.6M | $41.8M | $39.4M | $30.8M |
| Retained Earnings | -$6.8M | -$15.7M | -$51.0M | -$118.2M | -$243.8M | -$335.0M | -$417.4M | -$487.1M | -$464.7M |
| Total Equity | -$6.7M | -$15.5M | -$47.2M | $307.8M | $195.9M | $115.7M | $116.7M | $83.3M | $112.2M |
| Total Debt | $12.5M | $60.8M | 0 | $8.7M | $28.5M | $28.1M | $25.3M | $22.2M | $18.8M |
| Net Debt | $4.6M | $9.1M | -$154.7M | -$306.3M | -$181.3M | -$94.7M | -$106.1M | -$76.4M | -$109.9M |
| Working Capital | $5.7M | $49.1M | $150.9M | $305.3M | $192.1M | $112.4M | $114.4M | $80.6M | $116.7M |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 7.28 |
Profitability
| Return on Equity | -38.80% |
| Return on Invested Capital | -45.91% |
| Return on Assets | -34.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AARD · ABEO · AVTX · CRBU · ENTA · FENC · FHTX
Explore sector: Healthcare · Biotechnology
More sections of BDTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks